On July 23, 2020 Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, reported the completion of enrollment in its controlled, Phase 2 trial of relacorilant combined with nab-paclitaxel (Abraxane) in patients with metastatic, platinum-resistant ovarian cancer (Press release, Corcept Therapeutics, JUL 23, 2020, https://ir.corcept.com/news-releases/news-release-details/corcept-therapeutics-completes-enrollment-controlled-phase-2 [SID1234562288]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We achieved this milestone thanks in part to the hard work and enthusiasm of our clinical investigators," said Andreas Grauer, MD, Corcept’s Chief Medical Officer. "Data from our open-label, Phase 1/2 trial were very promising.1 We expect to have results from this larger, controlled trial in the first half of next year."

The trial has enrolled 177 patients at 28 sites in the United States, Canada and Europe. Participants were randomly assigned to receive either relacorilant in combination with nab-paclitaxel or nab-paclitaxel alone. The trial’s primary endpoint is progression free survival, with secondary endpoints including objective response rate and duration of objective response.2

About Relacorilant

Relacorilant is a non-steroidal, selective modulator of the glucocorticoid receptor, the receptor for cortisol which is activated when cortisol levels are high. Relacorilant does not bind to the body’s other hormone receptors. Corcept is studying relacorilant as a potential treatment for a variety of serious disorders, including Cushing’s syndrome and advanced adrenal, ovarian and pancreatic cancer. Relacorilant is proprietary to Corcept and is protected by composition of matter and method of use patents. Relacorilant has received orphan drug designation in the United States for the treatment of Cushing’s syndrome and pancreatic cancer.

On July 23, 2020 Clovis Oncology, Inc. (NASDAQ: CLVS) reported that it will announce its second quarter 2020 financial results on Thursday, August 6, 2020, after the close of the U.S. financial markets (Press release, Clovis Oncology, JUL 23, 2020, View Source [SID1234562287]). Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the company’s results in greater detail.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call is being webcast and can be accessed from the Clovis Oncology website at www.clovisoncology.com. A replay of the webcast will be available for 30 days.

Conference Call Details

Clovis will hold a conference call to discuss second quarter 2020 results on Thursday, August 6 at 4:30 p.m. ET. The conference call will be simultaneously webcast on the Company’s web site at www.clovisoncology.com, and archived for future review. Dial-in numbers for the conference call are as follows: U.S. participants (877) 698-7048, International participants (647) 689-5448, conference ID: 7155799.

On July 23, 2020 Cerus Corporation (Nasdaq:CERS) reported that its second quarter 2020 financial results will be released on Tuesday, August 4, 2020, after the close of the stock market (Press release, Cerus, JUL 23, 2020, View Source [SID1234562286]). The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at View Source Alternatively, you may access the live conference call by dialing (866) 235-9006 (U.S.) or (631) 291-4549 (international).

A replay will be available on Cerus’ website, or by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (international) and entering conference ID number 6681405. The replay will be available approximately three hours after the call through August 18, 2020.

On April 23, 2020 Cellesce reported that it has appointed Paul Jenkins as its CEO (Press release, Cellesce, JUL 23, 2020, View Source [SID1234562285]). Paul is a seasoned business development and senior management executive in the Life Science sector . He has amassed a wealth of deal-making and investment experience across a variety of therapeutic areas. Paul’s previous roles include VP Business Development at Catalent, CEO at Adjuvantix, and VP Business Development at West Pharmaceutical Services. Paul is also a strategic advisor to Yorkshire Cancer Research.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Paul obtained his PhD in Immunology and Vaccine Design from Plymouth University and attended the London Business School’s ‘Accelerated Development Programme.’

"We are delighted to have secured Paul as our CEO following a period as a consultant and Interim CEO," said John Allbrook, Non-Executive Chairman of Cellesce. "His background and experience in the industry, particularly with early-stage biotech companies, is particularly welcome as we begin to commercialise our organoid technology. Paul’s appointment adds credibility to the fast-developing realisation that organoids have an important role to play in the drug discovery arena and other significant application areas."

"I am excited to be joining Cellesce at this pivotal time in the company’s development. Organoid biology is playing an ever more important role in helping large Pharma to reduce the attrition rate in their drug development programs and Cellesce’s expertise and technology are well placed to drive their adoption faster," said Paul Jenkins.

Organoids are three-dimensional (3D) stem cell cultures that can self-organise into ex vivo ‘mini-organs.’ They facilitate the study of tumour pathology to enable cancer drug discovery. Organoids are closer to in vivo tumours than more conventional 2D cell line cultures and can provide more relevant pharmacological responses to drugs and antibodies. By using organoids in drug discovery screening assays, scientists can identify active compounds for further progression earlier in the drug discovery process and weed out less attractive compounds before incurring higher downstream costs.

On July 23, 2020 BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) reported that the company will report its second quarter 2020 financial results on Thursday, August 6, 2020 (Press release, BioCryst Pharmaceuticals, JUL 23, 2020, View Source [SID1234562284]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 877-303-8027 for domestic callers and 760-536-5165 for international callers and using conference ID # 5142479. A live webcast of the call and any slides will be available online at the investors section of the company website at www.biocryst.com. A telephone replay of the call will be available by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference ID # 5142479.